Optimal treatment of rhabdomyosarcoma (RMS) requires multidisciplinary approach, incorporating chemotherapy with local control. Although current therapies are built on cooperative group trials, a comprehensive standard of care to guide clinical decision making has been lacking, especially for relapsed patients. Therefore, we assembled a panel of pediatric and adolescent and young adult sarcoma experts to develop treatment guidelines for managing RMS and to identify areas in which further research is needed. We created algorithms incorporating evidence-based care for patients with RMS, emphasizing the importance of clinical trials and close integration of all specialties involved in the care of these patients.
INTRODUCTION
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, with approximately 350 cases diagnosed per year in the United States. 1 The 2013 World Health Organization classification system for RMS includes four subgroups: embryonal rhabdomyosarcoma (ERMS), alveolar rhabdomyosarcoma (ARMS), pleomorphic, and spindle cell/sclerosing. 2 There is tremendous variability in primary
METHODS
A group of multidisciplinary pediatric and adolescent and young adult sarcoma specialists from the United States was empaneled to discuss how we treat RMS and to identify current controversies regarding this disease. We held conference calls over 6 months where we reviewed data and shared our strategies to manage both common and rare clinical scenarios pertaining to optimal RMS management. At times, our group was uniform in practice decisions; however, there were significant differing treatment strategies. These in depth discussions were synthesized to develop consensus guidelines. We framed this review to address 10 key questions, which focus on the diagnosis, staging, and comprehensive management of RMS.
QUESTIONS

Question 1: Should testing for FOX01 fusion in tumor cells be done for all patients with RMS?
Approximately 75% of tumors with histologic features of ARMS demonstrate recurrent t(2;13) or t(1;13) translocations, resulting in fusion of the DNA binding domain of PAX3 (2q36.1) or PAX7 (1p36) with the carboxyl terminus of FOXO1 (13q14). 3 Importantly, ARMS lacking FOXO1 translocation has a gene expression signature and clinical behavior more similar to ERMS. 4 This key finding has led to a modernization of the classification of nonpleomorphic RMS into two major subgroups: fusion-positive RMS (FP-RMS) and fusion-negative RMS (FN-RMS). [4] [5] [6] Molecular testing (e.g., FISH, reverse transcription PCR, or next-generation sequencing) can readily identify PAX/FOXO1 fusions, and because results may impact treatment decisions, we recommend testing for FOXO1 fusions on all patients with alveolar or embryonal histology.
Spindle cell/sclerosing RMS (SRMS) has been newly identified as an official subtype, and there has been conflicting evidence about whether it behaves more similarly to ERMS or adult-type or pleomorphic RMS. 7 These tumors occur more frequently in males and recent data suggest worse prognosis for SRMS in adults when compared to children, in patients with parameningeal tumors, or when associated with MYOD1 mutations. 8, 9 In contrast, infants with SRMS and NCOA2 or VGLL2 translocations may have favorable outcomes. 8 At present, SRMS patients are stratified according to more established risk factors until more data are available to guide therapy for this uncommon subtype. The fourth subtype, pleomorphic RMS, is more common in adults and extremely rare in the pediatric population. We recommend that the pathology of pleomorphic RMS diagnosed in a pediatric patient be reviewed at a high volume sarcoma center.
Question 2: Is bone and bone marrow evaluation necessary for all patients with RMS?
RMS most often spreads to lymph nodes, lungs, cortical bone, and bone marrow. Initial staging has therefore traditionally included dedicated computed tomography (CT) scan of the chest to identify lung nodules, 99 Tc bone scintigraphy to detect skeletal metastases, and bilateral bone marrow aspiration and biopsy to assess marrow involvement. Cooperative group studies have often required this entire metastatic workup for all patients. However, the overall incidence of metastatic involvement is low, and so we recommend a risk-specific rather than disease-specific approach to staging (Fig. 1A) , based on the fact that nodal involvement, tumor invasiveness, and histologic subtype are the most powerful predictors of metastases. Retrospective data from 955 FN-RMS patients without nodal or lung disease treated on cooperative group studies suggest that the chance of metastases in bone or bone marrow is <1%. 10 Therefore, in these select patients (tumors < 5 cm, FN-RMS, no evidence of nodal disease), omitting assessments for bone and bone marrow disease is reasonable. We continue to obtain chest CT at initial diagnosis, although the yield of this study is low for FN-RMS patients without nodal disease. PET-CT is emerging as a useful test for staging RMS, and we routinely perform this for all newly diagnosed patients, as it may offer an additional assessment of regional lymph nodes. 11 Identification of nodal metastases is critically important in the management of RMS, and tissue sampling should be performed for all patients with clinically or radiographically suspicious lymphadenopathy.
Sampling of clinically normal lymph nodes is recommended in two specific situations. First, patients with paratesticular RMS over 10 years of age should undergo staging ipsilateral retroperitoneal lymph node dissection, as the ability to identify nodal disease by imaging remains unsatisfactory. 12 Second, nodal sampling is recommended for extremity tumors, as up to 23% of these patients will have regional lymphatic metastases even with normal sized nodes. 13 Sentinel lymph node biopsy is preferable when available, as it can identify therapychanging nodal disease that occasionally may not be appreciated with PET-CT. 14 In addition to assessment of nodal disease, fluid or effusion analysis is warranted when present, as cytologic evidence of malignancy in pleural or peritoneal fluid qualifies as metastatic disease. Radiographic or pathologic identification of body cavity tumor implants is also defined as metastasis. For patients with parameningeal RMS, cerebrospinal fluid should be evaluated. 15 Most pediatric oncologists in the United States use the International RMS Study (IRS) grouping and TNM staging, as opposed to traditional soft tissue sarcoma staging systems. 16 This system takes into account the prognostic significance of tumor site, size, and extent of resection, and allows for risk stratification (Fig. 1B) .
Question 3: Is genetic testing for cancer predisposition syndromes necessary for all RMS patients?
There is growing evidence that sarcoma patients in general may harbor underlying germline mutations more commonly than previously appreciated, leading to recommendations by some for broader genetic screening of newly diagnosed patients. 17, 18 RMS has been associated with several cancer predisposition syndromes, including neurofibromatosis type 1, Gorlin, Beckwith-Wiedemann, and Li-Fraumeni syndromes among others. These diagnoses have important implications not only for the patient but also for the siblings or found that <2% of 213 intermediate-risk RMS patients had germline TP53 mutations. 19 However, the incidence may be higher in patients diagnosed with RMS before age 3 years. 20 Furthermore, Hettmer and colleagues have reported germline TP53 mutations in 11 (73%) of 15 children whose tumors have anaplastic features. 18 The collection of germline data from RMS patients is ongoing, and new findings may help further refine guidelines for genetic testing. At present, it seems reasonable at a minimum to strongly consider referral for genetic 
Question 4: What is the optimal management of low-risk RMS?
Given the high rate of micrometastatic disease that leads to relapse in patients treated only with local therapy, all RMS patients are treated with adjuvant chemotherapy, with the extent of treatment based on established risk factors. There was strong consensus that, when feasible, all newly diagnosed RMS patients should be offered participation in a therapeutic clinical trial. Our definition of low-risk disease (Fig. 1B) 16 For these patients, we recommend 22 weeks of therapy composed of four cycles of vincristine, dactinomycin, and cyclophosphamide (VAC) followed by four cycles of vincristine and dactinomycin (VA), with a total cumulative cyclophosphamide exposure of 4.8 g/m 2 that may result in a lower incidence of infertility ( Fig. 2A) . 21 Alternatively, 45 weeks of VA may be administered with similar results, although with a significantly longer treatment course and increased medical costs ( Fig. 2A, Supplementary Table S1 ). 22, 23 Outcome for these patients is excellent, with 5-year survival greater than 90% (Fig. 1C) . However, given the poor results with low-risk therapy for patients whose tumors were Stage 1 (nonorbit) Group III or Stage 3 Group I-II, we believe such patients should be treated with intermediate-risk protocols. 24 
Question 5: Should irinotecan be used for treatment of intermediate-risk RMS?
Approximately 60% of newly diagnosed RMS patients are considered intermediate risk, and optimal treatment has evolved through sequential clinical trials, resulting in 65% 3-year event-free survival, with an inferior outcome for patients with FP-RMS (Fig. 1C) . 6 (Fig. 2A) .
Because the seven courses of irinotecan (each lasting 5 days) may be logistically problematic or poorly tolerated due to gastrointestinal toxicity, VAC chemotherapy alone may be reasonable in certain patients. 27, 31 This lack of benefit of the intensive "kitchen sink" approach for highrisk FP-RMS patients creates controversy over their management.
Question
Outside of a study (which should be strongly encouraged), we agreed that there are multiple acceptable options, but some in our group recommended limiting treatment to either VAC or VAC/VI, while others continue to offer the dose-intensive multiagent approach described after reviewing the risks and benefits of each approach, and also taking into consideration quality of life given the very poor prognosis of these patients (Fig. 2A). 
Question 7: What is the role of surgery and radiation therapy in the treatment of RMS?
Surgery and/or radiotherapy are essential to the optimal management of RMS regardless of stage or risk group. Local control options must be carefully considered at the time of diagnosis, and complete resection of primary tumor is desirable if it can be achieved with minimal morbidity and negative microscopic margins. 32 Second-look surgery to resect residual disease or positive margins may be considered, thus omitting the need for adjuvant radiation therapy in select cases. When up-front resection would result in significant morbidity, biopsy alone is recommended, as there is no advantage for debulking over biopsy alone in patients with Group III tumors. 33 Adjuvant radiotherapy is recommended for all patients except those with completely resected (margin-negative) FN-RMS ( Fig. 2A) . 34 Radiation dosages are based on the extent of resection, FOXO1 fusion status, nodal disease, and tumor site and size. For example, a patient with completely resected FN-RMS may receive no radiotherapy, while a patient with completely resected FP-RMS will receive 36 Gy to the primary site, and a patient with regional nodal involvement will receive 41.4 Gy even if surgical margins are negative. In patients with incompletely resected or gross disease, 50.4 Gy should be considered, except for orbital primaries in which 45 Gy is often used (Fig. 2A) . 35 However, patients with orbital RMS who failed to achieve a complete radiographic response to therapy had an increased local recurrence rate when receiving 45 Gy of radiation treatment, suggesting that this subset of patients may benefit from a higher dose (such as 50.4 Gy). 36 Given that patients with bulky Group III tumors > 5 cm have an increased risk of local recurrence, increasing the radiation dose to 59.4 Gy in these individuals is currently being investigated in a prospective clinical trial (NCT02567435). No studies have demonstrated a benefit for specific timing of radiotherapy, although radiation is most commonly initiated after four cycles of neoadjuvant chemotherapy. Recent data suggest that even when there is cranial nerve palsy or skull base erosion from parameningeal RMS, radiotherapy can safely and effectively be given at week 12 as long as neoadjuvant chemotherapy is started promptly. 37 In cases of very young children, delaying radiotherapy until later in treatment may be beneficial, although omission of XRT will result in an increased risk of local recurrence. 38 Furthermore, when tumors are close to vital structures, proton radiotherapy or brachytherapy should be considered to minimize side effects. 39 In cases when local control is excessively complex or difficult, referral to a medical center with extensive experience in both surgical and radiation management of complex RMS patients should be considered.
The majority of intermediate-risk RMS patients have only had a biopsy and are not resected before starting chemotherapy. Although historically these patients received radiotherapy alone for local control, delayed primary tumor resection following neoadjuvant chemotherapy may facilitate local control and allow lowering of radiotherapy dose, thus potentially reducing long-term sequelae. Recent data suggest that in select patients delayed primary excision with less radiation can achieve local control rates similar to historical controls treated with higher radiotherapy dosages ( Fig. 2A) . 40 Surgery and/or radiation remain important in the management of high-risk RMS with oligometastatic disease to decrease treatment failures. When there are widespread metastases at presentation, local control is often delayed until later in treatment, and may be customized to focus on the most symptomatic or critical sites. In almost all of these advanced cases, treatment is with palliative intent.
Question 8: How should patients with residual masses at the end of therapy be managed?
Patients who complete therapy for RMS frequently do not achieve complete radiographic response by cross-sectional imaging, though PET scans are often normal. This is likely due to tumor scarring or differentiation. Because the extent of tumor response does not predict survival, resection or biopsy of residual tumor is not recommended except in cases in which they are enlarging or painful. 41 Residual masses that remain PET avid are a challenge to manage. These patients have an increased risk of both local and metastatic relapse, and a decision whether to biopsy or resect a residual PET avid tumor should be made on a case-by-case basis weighing the risks of morbidity versus benefit. 42 Given the poor outcome for high-risk RMS patients, maintenance chemotherapy regimens have been tested in a small nonrandomized clinical trial but no conclusive benefit has been established. 43 We therefore do not generally recommend maintenance chemotherapy in RMS patients, except in the context of a clinical trial. However, the European Pediatric Soft Tissue Sarcoma Group 2005 clinical trial (NCT00379457) incorporates a maintenance regimen with vinorelbine and oral cyclophosphamide for certain IRS Group II and III patients. Results of this study may provide valuable information on the benefit and toxicity of maintenance chemotherapy for this population.
Patients should be followed closely after treatment (Fig. 2B) . Some providers recommend a baseline end-of-treatment PET/CT scan in high-risk patients, but we do not routinely obtain serial surveillance PET scans. Typically, surveillance MRI of the primary tumor and chest imaging are performed at 3-month intervals during the first year, with intervals increasing over time. Some providers recommend pulmonary surveillance with chest CT scan, whereas others use chest X-ray for all patients except those with previous pulmonary metastases. Imaging after 5 years is not routinely recommended. All patients should be followed throughout their life to monitor for late effects related to therapy. 45 For patients with suspected relapse, biopsy is recommended unless the diagnosis is unequivocal (Fig. 2C) . Given the systemic nature of RMS, patients generally are treated with chemotherapy in addition to local control. Surgery can be considered for lesions that can be resected with minimal morbidity. Radiotherapy is often used to treat the primary tumor site if not initially treated, and to treat metastatic sites such as bone or lung when such therapy is feasible. Radiotherapy may be initially delayed, particularly for metastatic sites, in an effort to assess the responsiveness and allow better bone marrow tolerance of systemic chemotherapy. The median progression-free survival following first recurrence/progression for all RMS patients is approximately 9 months. 44 Although no published data exist on the optimal length of salvage therapy, most patients receive at least eight cycles of chemotherapy if complete response is documented and tolerance is acceptable. Unfortunately, treatment often ends with either progressive disease or unacceptable toxicity.
Question
Enrollment on a clinical trial is preferable for patients with relapsed RMS. For those not on a therapeutic study, multiple salvage chemotherapy regimens with documented activity may be considered (Table 1) . [46] [47] [48] [49] [50] [51] [52] There has been no direct comparison of these therapies to identify one optimal treatment, so therapy decisions are often impacted by the extent and type of prior treatment, as well as patient condition and enthusiasm for further therapy. Our consensus recommendation for patients who demonstrate relapse after low-risk disease (who did not initially receive intensive therapy) is to administer irinotecan-based therapy or a more intensive 49, 53 Although carboplatin and temozolomide have also been used in combination salvage therapy, their specific contribution to efficacy is not clear. 54 For relapse of more heavily pretreated patients, we recommend the combination of cyclophosphamide, vinorelbine, and temsirolimus. 50 Cyclophosphamide combined with topotecan has also shown activity, although is more myelosuppressive than other regimens. 52 While these combinations have produced significant responses, the vast majority of patients ultimately develop disease progression, underscoring the need for new therapies.
Agents commonly used for adult soft tissue sarcoma, such as gemcitabine and docetaxel or pazopanib, have been less extensively studied in RMS. 46, 55, 56 Furthermore, there is little published data demonstrating the efficacy of tyrosine kinase inhibitors in the treatment of relapsed RMS. Intensification of therapy followed by autologous or allogeneic stem cell transplantation has also not been routinely helpful, and is generally done only in the context of a clinical trial. 57, 58 Although the use of molecular profiling or patient-derived xenografts to guide therapy is intuitively appealing and commonly done in the setting of recurrent disease, there are no prospective published data demonstrating that this strategy affects outcome for patients with relapsed RMS. Similarly, the role of immunotherapy, including checkpoint inhibitors (e.g., agents that target PD-1, PD-L1, or CTLA-4), immunomodulatory agents, or chimeric antigen receptor T-cell therapy, are being evaluated but efficacy has not yet been established.
Question 10. How should adults with RMS be managed?
Outcomes for RMS worsen with age, even when comparing patients age 15-19 years with those under 14 years. 59 The reasons for this are multifactorial and may include delays in presentation and access to care in sarcoma centers, poor adherence to aggressive treatment regimens, potential pharmacokinetic differences, and limited accrual on clinical trials. 60 There are important biologic differences in the tumors as well, with the more aggressive pleomorphic subtype comprising up to 43% of RMS diagnosed in adults. 61 This subtype behaves more like other adult soft tissues sarcomas, with less predictable chemotherapy sensitivity and historic survival rates <30%. 62 No formal trials have compared efficacy of various treatment regimens, although many patients receive adjuvant chemotherapy with anthracyclines and alkylating agents in combination with local control measures. It does not appear that conventional multiagent regimens used for pediatric patients routinely benefit those with pleomorphic RMS, and more data are needed about the biology and treatment for these tumors. In contrast, adults with nonpleomorphic RMS may indeed benefit from riskbased pediatric regimens, which have prompted cooperative groups to extend enrollment up to age 50. 63 
CONCLUSION
We describe a consensus approach to RMS that highlights recent discoveries while identifying areas in which further research is needed.
The complexity, rarity, and poor outcome of this disease underscore the need for an organized approach through clinical trial enrollment when possible, and patients clearly benefit most through wellcoordinated multidisciplinary care.
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